1,980 results match your criteria Combined B-Cell and T-Cell Disorders


Case Report: Combined Intravenous Infusion and Local Injection of CAR-T Cells Induced Remission in a Relapsed Diffuse Large B-Cell Lymphoma Patient.

Front Immunol 2021 19;12:665230. Epub 2021 Apr 19.

Department of Hematology/Hematological Lab, The Second Hospital of Anhui Medical University, Hefei, China.

Relapsed diffuse large B-cell lymphoma (DLBCL) is a disease with a poor prognosis. Recent clinical trials results showed chimeric antigen receptor (CAR) T cell therapy has a promising role in treating relapsed DLBCL. Unfortunately, patients with extranodal lesions respond poorly to CAR-T cells administered intravenously. Read More

View Article and Full-Text PDF

Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma.

Cancer Sci 2021 May 1. Epub 2021 May 1.

Department of lymphoma, Tianjin Medical University Cancer Institute and Hospital. National Clinical Research Center of Cancer, Key laboratory of Cancer Prevention and Therapy. Tianjin's Clinical Research Center for Cancer, the Sino-US center for Lymphoma and Leukemia Research, Tianjin, China.

The efficacy and side effects of the second-time humanized CD19 chimeric antigen receptor (CD19-CAR) T-cell therapy after unsuccessful first-time anti-CD19-CAR T-cell therapy and subsequent ibrutinib salvage treatment were observed in patients with refractory B-cell lymphoma. In our study, three patients with refractory mantle cell lymphoma (MCL) and four patients with refractory follicular lymphoma (FL) reached stable disease (SD), partial remission (PR), or progression of disease (PD) after first-time humanized anti-CD19-CAR T-cell therapy. They received ibrutinib as a salvage treatment and kept a SD in the following 7-16 months, but their disease progressed again during ibrutinib salvage treatment. Read More

View Article and Full-Text PDF

Programmed cell death protein-1 inhibitor combined with chimeric antigen receptor T cells in the treatment of relapsed refractory non-Hodgkin lymphoma: A case report.

World J Clin Cases 2021 Apr;9(10):2394-2399

Department of Hematology, Second Hospital of Hebei Medical University, Hebei Key Laboratory of Hematology, Shijiazhuang 050000, Hebei Province, China.

Background: Chimeric antigen receptor T cell (CART) therapy has benefited many refractory lymphoma patients, but some patients experience poor effects. Previous studies have shown that programmed cell death protein-1 (PD-1) inhibitors can improve and prolong the therapeutic effect of CAR-T cell treatment.

Case Summary: A 61-year-old male presented with 15-d history of diarrhea and lower-limb edema. Read More

View Article and Full-Text PDF

5-aminolevulinic acid combined with sodium ferrous citrate ameliorated lupus nephritis in a mouse chronic graft-versus-host disease model.

Int Immunopharmacol 2021 Apr 13;96:107626. Epub 2021 Apr 13.

Division of Transplantation Immunology, National Research Institute for Child Health and Development, Tokyo, Japan; Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Electronic address:

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by the abnormal activation of immune cells and hypersecretion of autoantibodies and causes irreversible chronic damage, such as lupus nephritis. Chronic graft-versus-host-disease (cGvHD) in mice induced by the injection of parental mouse lymphocytes into F1 hybrids leads to a disease similar to SLE. 5-aminolevulinic acid (5-ALA) is a key progenitor of heme, and its combination with sodium ferrous citrate (SFC) can up-regulate the heme oxygenase (HO-1) expression, resulting in an anti-inflammatory effect. Read More

View Article and Full-Text PDF

Clinicopathologic features of Good's syndrome: Two cases and literature review.

Open Med (Wars) 2021 1;16(1):532-539. Epub 2021 Apr 1.

Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.

Background: Good's syndrome (GS) is an immunodeficiency disease, causing thymoma, low or absent B-cells, hypogammaglobulinemia, and defects in cell-mediated immunity. The most common clinical presentation is recurrent infection, followed by refractory diarrhea, due to the immunodeficiency. However, there are only few reports on intestinal endoscopy and pathology. Read More

View Article and Full-Text PDF

Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis.

Int J Med Sci 2021 18;18(8):1786-1797. Epub 2021 Feb 18.

Department of Hematology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.

Multiple myeloma (MM) is incurable in spite of recent treatment improvements, highlighting the development of new therapies. Chimeric antigen receptor (CAR) T-cell therapy has dramatically changed the therapeutic effectiveness in high-risk B-cell malignancies. For relapsed/refractory multiple myeloma (RRMM), preclinical evaluations of CAR-T therapy have shown promising efficacy, thus various active clinical trials are under way. Read More

View Article and Full-Text PDF
February 2021

Tumor-infiltrating B cells and T cells correlate with postoperative prognosis in triple-negative carcinoma of the breast.

BMC Cancer 2021 Mar 16;21(1):286. Epub 2021 Mar 16.

Department of Diagnostic Pathology, Tokyo Women's Medical University, Medical Center East, 2-1-10 Nishiogu, Arakawa-ku, Tokyo, 116-8567, Japan.

Background: In this study, we investigated CD20+ TILs in triple-negative breast cancer (TNBC) and their relationship with T lymphocyte subsets (CD4+, CD8+, CD25+, and FOXP3+), including their combined prognostic value using an immunohistochemical staining method.

Methods: We investigated 107 patients with TNBC for whom a full-face section stained by hematoxylin and eosin between 2006 and 2018 at Dokkyo Medical University Hospital was available.

Results: The strongest association of infiltrating CD20+ TILs was with CD4+ TILs. Read More

View Article and Full-Text PDF

Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.

Am J Hematol 2021 Mar 16. Epub 2021 Mar 16.

Department of Hematology, Beijing Boren Hospital, Beijing, China.

The prognosis of relapsed acute lymphoblastic leukemia (ALL) after allogeneic transplantation is dismal when treated with conventional approaches. While single-target CD19 or CD22 chimeric antigen receptor (CAR) T-cell therapy has achieved high complete remission (CR) rates in refractory/relapsed B-ALL, it could not maintain a durable remission in most patients. To prolong relapse-free survival, we sequentially combined CD19 and CD22 CAR-T cells to treat post-transplant relapsed B-ALL patients with both CD19/CD22 antigen expression on lymphoblasts. Read More

View Article and Full-Text PDF

Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.

Front Immunol 2021 23;12:611366. Epub 2021 Feb 23.

Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.

Clinical trials have confirmed that chimeric antigen receptor (CAR) T cell therapies are revolutionizing approaches for treating several relapsed or refractory hematological tumors. Cytokine release syndrome (CRS) is an adverse event with high incidence during CAR-T treatment. A further understanding of the characteristics and related risk factors of CRS is important for effective management. Read More

View Article and Full-Text PDF
February 2021

Fetomaternal immune cross talk modifies T-cell priming through sustained changes to DC function.

J Allergy Clin Immunol 2021 Mar 5. Epub 2021 Mar 5.

Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, Munich, Germany. Electronic address:

Background: Prenatal exposure to infections can modify immune development. These environmental disturbances during early life potentially alter the incidence of inflammatory disorders as well as priming of immune responses. Infection with the helminth Schistosoma mansoni is widely studied for its ability to alter immune responsiveness and is associated with variations in coinfection, allergy, and vaccine efficacy in endemic populations. Read More

View Article and Full-Text PDF

Tumour-Infiltrating Lymphocytes (TILs) and PD-L1 Expression Correlate with Lymph Node Metastasis, High-Grade Transformation and Shorter Metastasis-Free Survival in Patients with Acinic Cell Carcinoma (AciCC) of the Salivary Glands.

Cancers (Basel) 2021 Feb 25;13(5). Epub 2021 Feb 25.

Department of Otorhinolaryngology, Head & Neck Surgery, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Waldstrasse 1, 91054 Erlangen, Germany.

Objectives: The aim of this study was to assess the number of tumour-infiltrating lymphocytes (TILs) and the expression of (PD-L1) in Acinic Cell Carcinoma (AciCC) of the salivary glands, to enable a correlation with clinico-pathological features and to analyse their prognostic impact.

Methods: This single centre retrospective study represents a cohort of 36 primary AciCCs with long-term clinical follow-up. Immunohistochemically defined immune cell subtypes, i. Read More

View Article and Full-Text PDF
February 2021

Loss of DIAPH1 causes SCBMS, combined immunodeficiency, and mitochondrial dysfunction.

J Allergy Clin Immunol 2021 Mar 1. Epub 2021 Mar 1.

PEDEGO Research Unit, University of Oulu, Oulu, Finland.

Background: Homozygous loss of DIAPH1 results in seizures, cortical blindness, and microcephaly syndrome (SCBMS). We studied 5 Finnish and 2 Omani patients with loss of DIAPH1 presenting with SCBMS, mitochondrial dysfunction, and immunodeficiency.

Objective: We sought to further characterize phenotypes and disease mechanisms associated with loss of DIAPH1. Read More

View Article and Full-Text PDF

Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.

JAMA 2021 03;325(9):843-854

Charité-Universitätsmedizin Berlin, Berlin, Germany.

Importance: Blinatumomab is a CD3/CD19-directed bispecific T-cell engager molecule with efficacy in children with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL).

Objective: To evaluate event-free survival in children with high-risk first-relapse B-ALL after a third consolidation course with blinatumomab vs consolidation chemotherapy before allogeneic hematopoietic stem cell transplant.

Design, Setting, And Participants: In this randomized phase 3 clinical trial, patients were enrolled November 2015 to July 2019 (data cutoff, July 17, 2019). Read More

View Article and Full-Text PDF

Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.

JAMA 2021 03;325(9):833-842

Department of Pediatrics, Benioff Children's Hospital and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco.

Importance: Standard chemotherapy for first relapse of B-cell acute lymphoblastic leukemia (B-ALL) in children, adolescents, and young adults is associated with high rates of severe toxicities, subsequent relapse, and death, especially for patients with early relapse (high risk) or late relapse with residual disease after reinduction chemotherapy (intermediate risk). Blinatumomab, a bispecific CD3 to CD19 T cell-engaging antibody construct, is efficacious in relapsed/refractory B-ALL and has a favorable toxicity profile.

Objective: To determine whether substituting blinatumomab for intensive chemotherapy in consolidation therapy would improve survival in children, adolescents, and young adults with high- and intermediate-risk first relapse of B-ALL. Read More

View Article and Full-Text PDF

Gene Editing Rescues In vitro T Cell Development of RAG2-Deficient Induced Pluripotent Stem Cells in an Artificial Thymic Organoid System.

J Clin Immunol 2021 Mar 1. Epub 2021 Mar 1.

Immune Deficiency Genetics Section, Laboratory of Clinical Immunology and Microbiology, DIR, NIAID, NIH, 10 Center Drive, Bldg. 10 CRC, Room 5-3950, Bethesda, MD, 20892-1456, USA.

Severe combined immune deficiency (SCID) caused by RAG1 or RAG2 deficiency is a genetically determined immune deficiency characterized by the virtual absence of T and B lymphocytes. Unless treated with hematopoietic stem cell transplantation (HSCT), patients with RAG deficiency succumb to severe infections early in life. However, HSCT carries the risk of graft-versus-host disease. Read More

View Article and Full-Text PDF

Successful Treatment of TCF3-HLF-positive Childhood B-ALL with Chimeric Antigen Receptor T-Cell Therapy.

Clin Lymphoma Myeloma Leuk 2021 Jan 28. Epub 2021 Jan 28.

Department of Hematology/Oncology, Key Laboratory of Pediatric Hematology and Oncology Ministry of Health, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address:

Background: TCF3-HLF positive leukemia represents a rare subtype of B-cell acute lymphoblastic leukemia (B-ALL), characterized by a high treatment failure rate despite intensive treatment and hematopoietic stem cell transplantation (HSCT).

Patients And Methods: Four consecutive children with TCF-HLF3-positive B-ALL who were refractory or relapsed with initial chemotherapy were treated with CD19-specific or combined CD19-and CD22-specific chimeric antigen receptor T-cell therapy (19/22 CAR-T) after conditioning regimen with fludarabine and cyclophosphamide. Clinical features, treatment responses, toxicity, and outcomes were analyzed retrospectively. Read More

View Article and Full-Text PDF
January 2021

A cytokine network profile delineates a common Th1/Be1 pro-inflammatory group of patients in four systemic autoimmune diseases.

Arthritis Rheumatol 2021 Feb 18. Epub 2021 Feb 18.

UMR1227, Lymphocytes B et Autoimmunité, Université de Brest, INSERM, CHU de Brest, Brest, France.

Objective: The effector T-cell and B-cell cytokine networks have been implicated in the pathogenesis of systemic autoimmune diseases (SAD), but an exploration of this association with the heterogeneity of clinical manifestations and immune profiles has not been carefully examined. The objective of this study was to examine whether cytokine profiles could delineate distinct groups of patients in four SAD (systemic lupus erythematosus, Sjögren syndrome, rheumatoid arthritis, and systemic sclerosis).

Methods: 179 patients and 48 healthy volunteers were enrolled in the multi-centric cross-sectional PRECISESADS. Read More

View Article and Full-Text PDF
February 2021

Adenylate kinase 2 expression and addiction in T-ALL.

Blood Adv 2021 Feb;5(3):700-710

Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Necker Enfants-Malades, Paris, France.

T-cell acute lymphoblastic leukemia (T-ALL) represents the malignant expansion of immature T cells blocked in their differentiation. T-ALL is still associated with a poor prognosis, mainly related to occurrence of relapse or refractory disease. A critical medical need therefore exists for new therapies to improve the disease prognosis. Read More

View Article and Full-Text PDF
February 2021

[The Relationship between Reducing of Peripheral Blood Treg in Primary Diffuse Large B-Cell Lymphoma Patients and Poor Prognosis].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021 Feb;29(1):91-97

Department of Hematology, Peking University Third Hospital, Beijing 100191, China,E-mail:

Objective: To explore the relationship between Treg cells level in peripheral blood and prognosis of patients with diffuse large B-cell lymphoma (DLBCL).

Methods: The percentage and absolute value of Treg cells in peripheral blood of DLBCL patients were detected by flow lytometry, and their correlation to prognosis was analyzed by survival analysis. The absolute count of Treg cells was detected by using maximally selected Log-rank statistic, and it was used as cutoff point to distinguish difference survival. Read More

View Article and Full-Text PDF
February 2021

Post-transplantation lymphoproliferative disorder after haematopoietic stem cell transplantation.

Ann Hematol 2021 Apr 6;100(4):865-878. Epub 2021 Feb 6.

Paediatric Haematology/Oncology and HSCT Department, Anna Meyer Children's University Hospital, Viale G. Pieraccini, 24, 50139, Florence, Italy.

Post-transplantation lymphoproliferative disorder (PTLD) is a severe complication of haematopoietic stem cell transplantation (HSCT), occurring in a setting of immune suppression and dysregulation. The disease is in most cases driven by the reactivation of the Epstein-Barr virus (EBV), which induces B cell proliferation through different pathomechanisms. Beyond EBV, many factors, variably dependent on HSCT-related immunosuppression, contribute to the disease development. Read More

View Article and Full-Text PDF

Age-Specific Imbalance of Circulating Tfh Cell Subsets and Its Association With Gout-Targeted Kidney Impairment.

Front Immunol 2020 11;11:625458. Epub 2021 Jan 11.

Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.

Objective: Gout is a chronic disease characterized by the deposition of monosodium urate (MSU) crystals in tissue. Study with a focus on adaptive immune response remains to be understood although innate immune response has been reported extensively in gout etiology. Our study attempted to investigate the association of gout-related immune cell imbalance with clinical features and comorbidity with renal impairment and the implicated pathogenesis the assessment of T and B cell subsets in different activity phases or with immune effects combined with the analyses of clinical parameters. Read More

View Article and Full-Text PDF
January 2021

[Newborn screening for severe T and B lymphocyte deficiencies in Switzerland].

Rev Med Suisse 2021 Jan;17(720-1):68-76

Service d'immunologie et allergie, Département de médecine, CHUV et Université de Lausanne, 1011 Lausanne.

Severe Combined Immunodeficiency (SCID) is one of the most severe forms of Primary Immunodeficiencies (PID) and leads to a potentially fatal course of disease without early and definitive treatment. Adequate management, from the first days of life, can improve the survival and outcome of patients with SCID. This can be achieved through newborn screening (NBS) based on the measurement of T-cell receptor excision circles (TREC). Read More

View Article and Full-Text PDF
January 2021

Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and/or refractory myeloma.

Cancer Med 2021 01 23;10(2):563-574. Epub 2020 Dec 23.

The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou, China.

The low rate of durable response against relapsed and/or refractory multiple myeloma (RRMM) in recent studies indicates that chimeric antigen receptor T-cell (CART) treatment is yet to be optimized. This study aims to investigate the safety and efficacy of sequential infusion of CD19-CART and B-cell maturation antigen (BCMA)-CARTs for RRMM with a similar 3 + 3 dose escalation combined with a toxicity sentinel design. We enrolled 10 patients, among whom 7 received autologous infusion and 3 received allogeneic infusion. Read More

View Article and Full-Text PDF
January 2021

Clinicopathological analysis of composite lymphoma: A two-case report and literature review.

Open Med (Wars) 2020 10;15(1):654-658. Epub 2020 Jul 10.

Department of Hematology, Shanxi Tumor Hospital, Taiyuan, Shanxi, People's Republic of China.

Objective: The objective of this study was to evaluate the clinicopathological features and treatment of composite lymphoma (CL) with cervical lymph node enlargement.

Methods: In this study, two cases of CL are presented. Biopsies of enlarged cervical lymph nodes by excision revealed two distinct types of lymphomas. Read More

View Article and Full-Text PDF

Immune Reconstitution After Gene Therapy Approaches in Patients With X-Linked Severe Combined Immunodeficiency Disease.

Front Immunol 2020 27;11:608653. Epub 2020 Nov 27.

Molecular and Cellular Immunology, Great Ormond Street Institute of Child Health, University College London, London, United Kingdom.

X-linked severe immunodeficiency disease (SCID-X1) is an inherited, rare, and life-threating disease. The genetic origin is a defect in the interleukin 2 receptor γ chain () gene and patients are classically characterized by absence of T and NK cells, as well as presence of partially-functional B cells. Without any treatment the disease is usually lethal during the first year of life. Read More

View Article and Full-Text PDF
November 2020

Myeloid-derived suppressor cells therapy enhance immunoregulatory properties in acute graft versus host disease with combination of regulatory T cells.

J Transl Med 2020 12 14;18(1):483. Epub 2020 Dec 14.

The Rheumatism Research Center, Catholic Research Institute of Medical Science, The Catholic University of Korea, 505 Banpo-dong, Seocho-gu, Seoul, 137-040, South Korea.

Background: Myeloid-derived suppressor cells (MDSCs) play a critical role in modulating the immune response and promoting immune tolerance in models of autoimmunity and transplantation. Regulatory T cells (Tregs) exert therapeutic potential due to their immunomodulatory properties, which have been demonstrated both in vitro and in clinical trials. Cell-based therapy for acute graft-versus-host disease (aGVHD) may enable induction of donor-specific tolerance in the preclinical setting. Read More

View Article and Full-Text PDF
December 2020

Somatic reversion of pathogenic DOCK8 variants alters lymphocyte differentiation and function to effectively cure DOCK8 deficiency.

J Clin Invest 2021 Feb;131(3)

Garvan Institute of Medical Research, Sydney, New South Wales, Australia.

Inborn errors of immunity cause monogenic immune dysregulatory conditions such as severe and recurrent pathogen infection, inflammation, allergy, and malignancy. Somatic reversion refers to the spontaneous repair of a pathogenic germline genetic variant and has been reported to occur in a number of inborn errors of immunity, with a range of impacts on clinical outcomes of these conditions. DOCK8 deficiency due to biallelic inactivating mutations in DOCK8 causes a combined immunodeficiency characterized by severe bacterial, viral, and fungal infections, as well as allergic disease and some cancers. Read More

View Article and Full-Text PDF
February 2021

Lymphocyte-depleting chemotherapy for aggressive hematologic malignancies in two patients with positive SARS-CoV-2 PCR.

Leuk Res 2021 01 13;100:106473. Epub 2020 Nov 13.

Alpert Medical School of Brown University, Providence, RI, United States; Division of Hematology-Oncology, Rhode Island Hospital, Providence, RI, United States.

View Article and Full-Text PDF
January 2021

EP4 receptor agonist L-902688 augments cytotoxic activities of ibrutinib, idelalisib, and venetoclax against chronic lymphocytic leukemia cells.

Biochem Pharmacol 2021 01 3;183:114352. Epub 2020 Dec 3.

University of Ljubljana, Faculty of Pharmacy, Aškerčeva cesta 7, 1000 Ljubljana, Slovenia. Electronic address:

Treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) has significantly improved more recently with the approval of several new agents, including ibrutinib, idelalisib, and venetoclax. Despite the outstanding efficacies observed with these agents, these treatments are sometimes discontinued due to toxicity, unresponsiveness, transformation of the disease and/or resistance. Constitutive NF-κB activation that protects CLL cells from apoptotic stimuli represents one of molecular mechanisms that underlie the emergence of drug resistance. Read More

View Article and Full-Text PDF
January 2021

Innate Immunity and Biological Therapies for the Treatment of Sjögren's Syndrome.

Int J Mol Sci 2020 Dec 1;21(23). Epub 2020 Dec 1.

Department of Molecular Medicine, The Scripps Research Institute, 10550 North Torrey Pines Rd., La Jolla, CA 92037, USA.

Sjögren's syndrome (SS) is a systemic autoimmune disorder affecting approximately 3% of the population in the United States. This disease has a female predilection and affects exocrine glands, including lacrimal and salivary glands. Dry eyes and dry mouths are the most common symptoms due to the loss of salivary and lacrimal gland function. Read More

View Article and Full-Text PDF
December 2020